Skip to content
ezGLP
Toggle navigation menu
Sign in
All research profiles

Longevity

Epitalon

Prepared by the ezGLP team. Sources last checked . Profile reviewed .

Also known as Epithalon

Routes represented in the knowledgebase: Subcutaneous (SubQ).

Educational overview

Epitalon is listed in the ezGLP knowledgebase under Longevity. Evidence and regulatory status can vary by formulation, route, and jurisdiction.

Epitalon (also spelled Epithalon or Epithalone) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. It was designed in the late 1990s by Vladimir Khavinson's group in St. Petersburg to mimic Epithalamin, a bovine pineal gland extract that the same laboratory had studied for decades. It is grouped with so-called geroprotective or longevity peptides. Proposed mechanisms drawn from cell and animal work include stimulation of telomerase activity, modulation of melatonin synthesis in the pineal gland, antioxidant effects, and changes in gene expression in neuroendocrine tissue. A 2025 review noted that the precise mechanism remains unverified and that physico-chemical characterization of the peptide is limited.

The evidence base is dominated by in vitro and animal studies, almost all originating from one Russian research network. Cell-line work, including a 2025 paper, reports increased telomere length in human cell lines through telomerase upregulation or alternative lengthening. Aged rhesus monkeys showed restored nocturnal melatonin and altered glucose handling after treatment. Rodent studies report reduced tumor incidence and lifespan changes. Human data concern mainly Epithalamin, the parent extract: a 12-year randomized study in 79 elderly coronary patients in Kiev reported lower mortality, but it was small, single-center, and never independently replicated. Trials of the tetrapeptide itself are limited to small studies from the same group.

Epitalon is not an approved medicine in any jurisdiction. In the United States it was placed in 2023 on the FDA list of bulk drug substances that may present significant safety risks when compounded; the agency stated it had identified no safety-related information for the proposed route and could not judge whether the product would cause harm. Material sold as Epitalon is therefore research-grade powder or an unapproved compounded injection. It is most often described as a subcutaneous injectable, though intranasal and oral forms are marketed. Epitalon is not named on the WADA Prohibited List, but the S0 category covers non-approved pharmacological substances generally.

Epitalon is supplied as a lyophilized powder and reconstituted before injection. No human pharmacokinetic study has been published, so the library carries no half-life estimate and there is no reference value for how long the peptide persists after a dose. Storage temperature and beyond-use time follow the product or pharmacy label. Because the peptide is usually taken in short courses separated by long gaps, a dose log that records course start and end dates, vial lot, reconstitution date, and concentration is the main way to reconstruct exposure later. An inventory record tied to lot numbers matters because identity and purity of research-grade material are not independently verified.

Category
Longevity
Routes represented
Subcutaneous (SubQ)
Storage context
Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.

Published literature

Safety evidence

Serious or important: potential immunogenicity, aggregation, impurity, or product-quality risks.

A dependable route-specific human interaction and side-effect profile is not established; this is not evidence of no risk.

Safety evidence source

Common questions

Does Epitalon actually lengthen telomeres?

In cultured human cells, yes: several in vitro studies, including a 2025 paper, report increased telomerase activity and longer telomeres after exposure. Whether this happens in living humans at meaningful levels has not been shown. No controlled human trial has measured telomere length as an outcome, and the animal data come almost entirely from one research group, so the claim rests on cell culture evidence rather than clinical results.

Has Epitalon been tested in humans?

Only in small studies from the Khavinson network, mostly published in Russian-language journals. The best-known human data concern Epithalamin, the pineal extract the tetrapeptide was designed to mimic: a 12-year randomized study in 79 elderly coronary patients reported lower mortality. That trial was small, single-center, and unreplicated, and the FDA states it has found no safety information for Epitalon by the proposed injectable route.

Is Epitalon legal or FDA approved?

Epitalon is not approved for human use anywhere. In 2023 the FDA listed it among bulk substances that may present significant safety risks in compounding, citing immunogenicity concerns and an absence of safety data. That listing means compounders cannot routinely prepare it, and products sold online are research chemicals rather than medicines. Legal status for possession varies by country and is separate from approval.

What is the difference between Epitalon and Epithalamin?

Epithalamin is a polypeptide extract of bovine pineal glands developed in the Soviet Union and studied for decades by the same laboratory. Epitalon is a four-amino-acid synthetic peptide, Ala-Glu-Asp-Gly, created to reproduce the extract's activity with a defined chemical structure. Most long-term human observations refer to Epithalamin, while cell and animal mechanism studies mostly involve Epitalon, so results are not interchangeable.

Further reading

Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.

For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live. Consult a licensed healthcare professional.